tiprankstipranks
GlaxoSmithKline (GB:GSK)
LSE:GSK

GlaxoSmithKline (GSK) Share Price & Analysis

199 Followers

GSK Stock Chart & Stats

Day’s Range0p - 0p
52-Week Range1,276.33p - 1,547.49p
Previous Close1,436p
Volume679.42K
Average Volume (3M)7.69M
Market Cap
£58.75B
Enterprise Value71.36B
Total Cash (Recent Filing)£7.88B
Total Debt (Recent Filing)£20.99B
Price to Earnings (P/E)9.6
Beta0.56
Jan 31, 2024
0.19 (0.01%)
Share Statistics
EPS (TTM)1.50
Shares Outstanding4,095,026,002
10 Day Avg. Volume11,123,383
30 Day Avg. Volume7,685,763
Standard Deviation0.05
R-Squared0.29
Alpha0.00638
Financial Highlights & Ratios
Price to Book (P/B)-615.37
Price to Sales (P/S)480.31
Price to Cash Flow (P/CF)703.90
P/FCF Ratio655.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
Price Target Upside4.94% Upside
Rating ConsensusHold
Number of Analyst Covering10


Financials

Annual

Ownership Overview

10.12% Mutual Funds
10.00% Other Institutional Investors
78.61% Public Companies and Individual Investors

GSK FAQ

What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest share price was 1276.33p and its highest was 1547.49p in the past 12 months.
    What is GlaxoSmithKline’s market cap?
    Currently, no data Available
    When is GlaxoSmithKline’s upcoming earnings report date?
    GlaxoSmithKline’s upcoming earnings report date is Jan 31, 2024 which is in 57 days.
      How were GlaxoSmithKline’s earnings last quarter?
      GlaxoSmithKline released its earnings results on Nov 01, 2023. The company reported 0.504p earnings per share for the quarter, beating the consensus estimate of 0.456p by 0.048p.
        Is GlaxoSmithKline overvalued?
        According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does GlaxoSmithKline pay dividends?
          GlaxoSmithKline pays a Annually dividend of 14p which represents an annual dividend yield of 3.88%. See more information on GlaxoSmithKline dividends here
            What is GlaxoSmithKline’s EPS estimate?
            GlaxoSmithKline’s EPS estimate is £0.31.
              How many shares outstanding does GlaxoSmithKline have?
              GlaxoSmithKline has 4,115,045,400 shares outstanding.
                What happened to GlaxoSmithKline’s price movement after its last earnings report?
                GlaxoSmithKline reported an EPS of 0.504p in its last earnings report, beating expectations of 0.456p. Following the earnings report the stock price went down -2.36%.
                  Which hedge fund is a major shareholder of GlaxoSmithKline?
                  Currently, no hedge funds are holding shares in GB:GSK

                  ---

                  Company Description

                  GlaxoSmithKline

                  In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.

                  ---

                  Top 5 ETFs holding GSK

                  Name
                  Market Value
                  Smart Score
                  BMO MSCI AllCntryWrl
                  $1.55M
                  8
                  Affinity World Leaders Equity ETF
                  $248.27K
                  8
                  Up to five ETFs with an Outperform Smart Score that hold GSK. The ETFs are listed according to market value of GSK within the ETF

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Smith & Nephew
                  Genedrive
                  Futura Medical

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis